Cardiology

New anti-clotting drugs linked to lower risk of serious bleeding

New drugs known as direct oral anticoagulants (DOACs) used to treat serious blood clots are associated with reduced risks of major bleeding compared with the older anti-clotting drug, warfarin, finds a study in The BMJ today.

Cardiology

Interruption of apixaban doesn't impact bleeding in A-fib

(HealthDay)—For patients undergoing catheter ablation for nonvalvular atrial fibrillation (AF), both uninterrupted and minimally interrupted apixaban are associated with a very low rate of thromboembolic events, according ...

Diseases, Conditions, Syndromes

Lower risk of gastrointestinal bleeding for apixaban

(HealthDay)—For patients receiving direct oral anticoagulant (DOAC) agents for non-valvular atrial fibrillation, apixaban is associated with a lower risk of gastrointestinal (GI) bleeding than rivaroxaban or dabigatran, ...

Cardiology

Non-vitamin K oral anticoagulants vary in assay effects

(HealthDay)—Non-vitamin K oral anticoagulants exhibit variable effects on coagulation assays, according to a study published in the Sept. 16 issue of the Journal of the American College of Cardiology.

Cardiology

Newer anticoagulants linked to gastrointestinal bleeding

(HealthDay)—Patients taking the new generation of oral anticoagulants appear to have a higher risk of gastrointestinal bleeding compared with standard care, particularly when treated for venous thrombosis or acute coronary ...

page 1 from 2